Xenon Pharmaceuticals

US · XENE #2361 by market cap Listed 2015

36.41 -0.16 -0.44%

Live - 5344 symbols - heartbeat 215s ago · 2026-10-08 06:17

Pre-market 36.05 -0.99%

After-hours 36.00 -1.13%

Overnight 36.40 -0.03%

Market cap: 3.53B
P/E (TTM): -7.68
P/B: 2.84
EPS: -4.36
Div yield: 0.00%
52W pos: 2%

Reader sentiment Are you bullish or bearish on XENE?

Anonymous reader poll. Unscientific, not investment advice.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc. is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Founded: 1996
CEO: Mr. Ian C. Mortimer
Employees: 370
Headquarters: Burnaby, British Columbia, Canada
Fiscal year end: 12-31
Website: xenon-pharma.com

Company profile

Exchange: US
Symbol: XENE
Market-cap rank: #2361
Listing date: 2015-04-02
Market cap: 3.53B
Float cap: 3.31B
Shares out: 96.84M
Float shares: 90.90M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 06:17:42 · For reference only, not investment advice and not tailored to your situation.